Intravitreal Conbercept for choroidal neovascularisation secondary to pathological myopia in real-life setting in China

Abstract Background: To evaluate the 12-month efficacy and safety of intravitreal conbercept for myopic choroidal neovascularization (CNV). Methods: A retrospective, observational study. Thirty-four eyes of 34 pathologic myopic patients with CNV were treated with intravitreal conbercept (IVC) 0.5 mg with a follow up of 12 months. After the first injection, administration of conbercept followed a pro re nata (PRN) regimen. Outcomes included best corrected visual acuity (BCVA), central retinal thickness (CRT), CNV size, the total number of treatments, and adverse events. Results: The mean patient age was 55.88 ± 16.17 years, and mean eye spherical equivalent was − 8.72 ± 3.75 D. The mean number of IVC over 12 months was 2.12 ± 0.69. Overall, best-corrected visual acuity（BCVA）improved from 0.86 ± 0.33 logMAR at baseline to 0.44 ± 0.32 logMAR at month 12 ( P < 0.001 ), mean improvement of vision was 4.12 ± 2.69 Snellen lines . Mean central retinal thickness reduced from 285.9 ± 104.6 μm at baseline to 192.1 ± 97.5 μm at month 12 (P < 0.001). Mean CNV size decreased from 0.52 ± 0.38 mm 2 at baseline to 0.31 ± 0.19 mm 2 at 12 months (P < 0.05). All the 34 eyes had reduced or stable size of CNV, thirty-two eyes (94.12%) showed absence of CNV leakage at the end of the study period. No severe complications were observed. Conclusion: Intravitreal conbercept 0.5mg was safe and effective for treatment of myopic CNV over 12 months in real-life setting.